Pfeiffer Cells
USD$700.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | Pfeiffer is a human diffuse large B-cell lymphoma (DLBCL) cell line derived from the malignant lymphoid tissue of an adult patient. It represents a mature B-cell neoplasm and grows in suspension as single cells and small aggregates under standard culture conditions. Morphologically, Pfeiffer cells display features typical of large transformed B lymphocytes, including a high nuclear-to-cytoplasmic ratio, prominent nucleoli, and dispersed chromatin. The cell line expresses B-cell-associated surface markers, including CD19, CD20, CD22, and surface immunoglobulin, consistent with its origin from germinal center or post-germinal center B cells. At the molecular level, Pfeiffer cells harbor genetic alterations characteristic of aggressive B-cell lymphomas. These commonly include abnormalities affecting key oncogenic pathways such as BCL6 deregulation and alterations in signaling cascades involved in proliferation and survival, including NF-κB and PI3K/AKT pathways. Like many DLBCL models, Pfeiffer exhibits complex karyotypic changes and somatic mutations in genes frequently implicated in lymphomagenesis. The cell line has been included in large-scale genomic and pharmacogenomic profiling efforts, supporting its use as a representative model for studying the genetic heterogeneity and therapeutic vulnerabilities of DLBCL. Functionally, Pfeiffer is widely used to investigate mechanisms of B-cell receptor signaling, antibody-dependent cellular cytotoxicity (ADCC), and responses to targeted agents such as anti-CD20 monoclonal antibodies, kinase inhibitors, and epigenetic modulators. Its robust CD20 expression makes it a suitable in vitro model for evaluating rituximab-mediated immune effector functions. Consequently, Pfeiffer serves as a valuable experimental system for dissecting molecular drivers of aggressive B-cell lymphoma and for preclinical testing of novel immunotherapeutic and small-molecule strategies. |
|---|---|
| Organism | Human |
| Tissue | Pleural effusion |
| Disease | Diffuse large B-cell lymphoma |
| Synonyms | PFEIFFER |
Characteristics
| Age | Adult |
|---|---|
| Gender | Male |
| Ethnicity | Caucasian |
| Morphology | lymphoblast |
| Cell type | B-cell |
| Growth properties | Suspension |
Regulatory Data
| Citation | Pfeiffer (Cytion catalog number 305850) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_3326 |
Biomolecular Data
| Mutational profile | Mutation: p.Arg1171Cys, Heterozygous |
|---|
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | None |
| Doubling time | 24-30 hours |
| Seeding density | 2 to 10 x 105 /ml |
| Freeze medium | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305850-280126 | Certificate of Analysis | 05. Mar. 2026 | 305850 |